Heart failure & cardiomyopathies
Identifying Patients at Risk: Multi-Centre Comparison of HeartMate 3 and HeartWare Left Ventricular Assist Devices
Main finding · SurvivalResult — go to the resultHazard ratio 1.46 95% CI 1.14–1.85Authors' conclusion
HM3 patients have a significantly better survival and a lower incidence of ischaemic strokes and pump thrombosis than HVAD patients. This survival difference persisted after 2 years of implantation.
Study context
- Population
- Patients with LV assist devices at centres implanting both HVAD and HM3458 matched
- Participants
- 1,021 patients
- Exposure
- HM3 vs HVAD
- Outcome
- Survival
Methodological detailsmulticentre, international, propensity-score matched
- Multicentre
- International
- Propensity-score matched
Main finding
As reported in the abstract
median follow-up 23 months
Hazard ratio
1.46
95% CI 1.14–1.85
P < 0.01
HVADvs HM3
HR 1.46 (95% CI 1.14–1.85); P < 0.01
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Conditional survival >2 years (landmark analysis) · >2 years after implantationSignificant difference | P = 0.03 |
Pre-operative variable × device type interactions
- None of the pre-operative variable interactions were significant
Safety
| Outcome | P value |
|---|---|
| Pump thrombosisLess with HM3 | P < 0.01 |
| Ischaemic strokeLess with HM3 | P < 0.01 |
Haemorrhagic stroke, right HF, driveline infection, major bleeding
- No difference
Original publication
Identifying Patients at Risk: Multi-Centre Comparison of HeartMate 3 and HeartWare Left Ventricular Assist Devices. ESC Heart Fail. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →